Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ENT011
MIFTS: 55

Enterocolitis

Categories: Gastrointestinal diseases, Infectious diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Enterocolitis

About this section

MalaCards integrated aliases for Enterocolitis:

Name: Enterocolitis 57 29 54 17 70

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal recessive


HPO:

31
enterocolitis:
Inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

OMIM® 57 226150
ICD10 32 A04.7
MedGen 41 C0014356
UMLS 70 C0014356
Sources

Summaries for Enterocolitis

About this section
MalaCards based summary : Enterocolitis is related to perinatal necrotizing enterocolitis and intestinal perforation. An important gene associated with Enterocolitis is NLRC4 (NLR Family CARD Domain Containing 4), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Ceftriaxone and Iron have been mentioned in the context of this disorder. Affiliated tissues include breast, heart and lung, and related phenotypes are hematochezia and abdominal distention

More information from OMIM: 226150
Sources

Related Diseases for Enterocolitis

About this section

Diseases related to Enterocolitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 965)
# Related Disease Score Top Affiliating Genes
1 perinatal necrotizing enterocolitis 32.1 TNF TLR4 IL6 IL10 FABP2 CXCL8
2 intestinal perforation 31.0 TNF TLR4 IL6 FABP2
3 food allergy 30.9 TNF TLR4 IL10 CXCL8
4 inflammatory bowel disease 30.7 TNF TLR4 IL6 IL10 CXCL8 CD14
5 neutropenia 30.7 TNF IL6 IL10 CXCL8
6 ileus 30.6 TNF IL6 IL10
7 hemolytic uremic syndrome, atypical 1 30.5 CFH CFB CD46 C3
8 gastroenteritis 30.5 TNF IL6 IL10 CXCL8
9 campylobacteriosis 30.4 TLR4 IL10
10 crohn's disease 30.3 TNF TLR4 IL6 IL10 CXCL8
11 disseminated intravascular coagulation 30.3 TNF IL6 IL10
12 compartment syndrome 30.3 TNF IL6 FABP2
13 typhoid fever 30.3 TNF TLR4 IL6
14 dysentery 30.3 TNF IL6 IL10 CXCL8
15 ileitis 30.2 TNF TLR4 IL6 FABP2
16 vasculitis 30.2 TNF IL6 C3
17 colitis 30.1 TNF TLR4 IL6 IL10 CXCL8
18 acquired immunodeficiency syndrome 30.1 TNF IL6 IL10
19 peritonitis 30.1 TNF TLR4 IL6 IL10 CXCL8 CD14
20 ulcerative colitis 30.1 TNF TLR4 IL6 IL10 CXCL8
21 graft-versus-host disease 30.1 TNF IL6 IL10
22 appendicitis 30.1 TNF TLR4 IL6 IL10 CXCL8
23 chorioamnionitis 30.0 TNF TLR4 IL6 IL10 CXCL8
24 disease by infectious agent 30.0 TNF TLR4 IL6 IL10
25 pre-eclampsia 30.0 TNF TLR4 IL6 IL10 CXCL8
26 exanthem 30.0 TNF IL6 IL10 CXCL8
27 pouchitis 29.9 TNF TLR4
28 spondylarthropathy 29.9 TNF TLR4
29 gastroesophageal reflux 29.9 TNF IL6 CXCL8
30 portal hypertension 29.9 TNF TLR4 CXCL8
31 cerebral palsy 29.9 TNF TLR4 IL6 IL10 CXCL8
32 synovitis 29.8 TNF IL6 CXCL8
33 macrophage activation syndrome 29.8 TNF NLRC4
34 myocarditis 29.8 TNF TLR4 IL6 IL10
35 esophagitis 29.8 TNF IL6 IL10 CXCL8
36 diarrhea 29.8 TNF TLR4 IL6 IL10 CXCL8 CD46
37 prosthetic joint infection 29.8 TLR4 IL6
38 pustulosis of palm and sole 29.8 TNF CXCL8
39 cardiogenic shock 29.8 TNF IL6
40 reactive arthritis 29.8 TNF TLR4 IL6 IL10 CXCL8
41 hemophagocytic lymphohistiocytosis 29.7 TNF IL10 CXCL8
42 placenta disease 29.7 TNF IL6 CXCL8
43 chemical colitis 29.7 TNF IL10
44 cholera 29.7 TNF IL6 IL10
45 respiratory failure 29.7 TNF TLR4 IL6 IL10 CXCL8
46 plague 29.7 TNF TLR4 IL6 IL10
47 lung disease 29.7 TNF TLR4 IL6 IL10 CXCL8
48 toxic shock syndrome 29.7 TNF TLR4 IL6 IL10 CXCL8 CD14
49 proteasome-associated autoinflammatory syndrome 1 29.7 TNF TLR4 IL6 IL10 CXCL8
50 dermatitis 29.7 TNF IL6 IL10 CXCL8

Graphical network of the top 20 diseases related to Enterocolitis:



Diseases related to Enterocolitis
Sources

Symptoms & Phenotypes for Enterocolitis

About this section

Human phenotypes related to Enterocolitis:

31
# Description HPO Frequency HPO Source Accession
1 hematochezia 31 HP:0002573
2 abdominal distention 31 HP:0003270
3 enterocolitis 31 HP:0004387
4 ulcerative colitis 31 HP:0100279

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
G I:
ulcerative colitis
bloody diarrhea
pseudomembranous enterocolitis

Abdomen:
swelling

Clinical features from OMIM®:

226150 (Updated 20-May-2021)

MGI Mouse Phenotypes related to Enterocolitis:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 C3 CD14 CFB CFH FABP2 IL10
2 hematopoietic system MP:0005397 10.11 C3 CD14 CFB CFH IL10 IL6
3 cardiovascular system MP:0005385 10.08 C3 CD46 CFB CFH IL10 IL6
4 immune system MP:0005387 10.06 C3 CD14 CFB CFH IL10 IL6
5 adipose tissue MP:0005375 9.97 C3 CD14 FABP2 IL6 TLR4 TNF
6 liver/biliary system MP:0005370 9.85 C3 FABP2 IL10 IL6 TLR4 TNF
7 muscle MP:0005369 9.8 C3 CFH IL10 IL6 TLR4 TNF
8 reproductive system MP:0005389 9.76 C3 CD46 CFB IL10 IL6 NLRC4
9 renal/urinary system MP:0005367 9.73 C3 CFB CFH FABP2 IL6 TLR4
10 skeleton MP:0005390 9.56 C3 CD14 CFB IL10 IL6 NLRC4
11 vision/eye MP:0005391 9.17 C3 CD46 CFH IL10 IL6 TLR4
Sources

Drugs & Therapeutics for Enterocolitis

About this section

Drugs for Enterocolitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
2
Iron Approved Phase 4 7439-89-6 23925 29936
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
5
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
6
Vancomycin Approved Phase 4 1404-90-6 441141 14969
7
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
8
Teicoplanin Approved, Investigational Phase 4 61036-62-2
9
Zinc Approved, Investigational Phase 4 7440-66-6 32051
10
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
11
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
12
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
13
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7 5280489
14
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
15 Antioxidants Phase 4
16 Hormones Phase 4
17 Calcium, Dietary Phase 4
18 Trace Elements Phase 4
19 Nutrients Phase 4
20 Micronutrients Phase 4
21 Chelating Agents Phase 4
22 Antiemetics Phase 4
23 Carotenoids Phase 4
24 Hormone Antagonists Phase 4
25 Iron Chelating Agents Phase 4
26 glucocorticoids Phase 4
27 Calciferol Phase 4
28 Antineoplastic Agents, Hormonal Phase 4
29
Picolinic acid Phase 4 98-98-6 1018
30 Provitamins Phase 4
31 Protective Agents Phase 4
32 Anti-Inflammatory Agents Phase 4
33 Antirheumatic Agents Phase 4
34 Amebicides Phase 4
35 Gentamicins Phase 4
36 Vitamins Phase 4
37 Pharmaceutical Solutions Phase 4
38 Dermatologic Agents Phase 4
39 Antibiotics, Antitubercular Phase 4
40
Calcium Nutraceutical Phase 4 7440-70-2 271
41
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
42
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
43
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
44
Rifampicin Approved Phase 3 13292-46-1 5458213 5381226
45
Glycerol Approved, Investigational Phase 3 56-81-5 753
46
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
47
Azithromycin Approved Phase 3 83905-01-5 55185 447043
48
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
49
Clarithromycin Approved Phase 3 81103-11-9 84029
50
Loperamide Approved Phase 2, Phase 3 53179-11-6 3955

Interventional clinical trials:

(show top 50) (show all 274)
# Name Status NCT ID Phase Drugs
1 The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis Unknown status NCT01278017 Phase 4 ceftriaxone
2 The Effect of Withholding Feeds During Red Blood Cell Transfusion on Development of TRAGI in Very Low Birth Weight Infants Unknown status NCT02132819 Phase 4
3 The Effect of Co-administered β-Carotene, Vitamin D3, Zinc and Antenatal Steroid Therapy on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates Unknown status NCT03366584 Phase 4 Dexamethasone
4 Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis Unknown status NCT02343562 Phase 4
5 Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection Unknown status NCT02237859 Phase 4 Vancomycin
6 Effect of Melatonin on Feeding Intolerance and Incidence of Necrotizing Enterocolitis in Preterm Infants Completed NCT04304807 Phase 4 Melatonin 20 mg;Traditional antibiotic treatment
7 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
8 Postmarketing Study of Probiotics Medication in Childhood Diarrhea Completed NCT00463190 Phase 4 Biothree
9 Exploratory Study of Impact of Oral Metronidazole, Vancomycin and Fidaxomicin on the Extent and Quantity of Host Carriage and Environmental Contamination With C. Difficile Completed NCT02057198 Phase 4 Fidaxomicin;Metronidazole;Vancomycin
10 Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
11 Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics Completed NCT02951702 Phase 4 Vancomycin Oral
12 An Open-label, Randomized Study to Assess Inhibition of Spore Production in Patients With Clostridium Difficile Infections: Fidaxomicin Versus Vancomycin Completed NCT01818141 Phase 4 Vancomycin;Fidaxomicin
13 NICU Antibiotics and Outcomes Trial Recruiting NCT03997266 Phase 4 Ampicillin;Gentamycin;Normal saline
14 A Comparison of Fidaxomicin and Oral Vancomycin for the Treatment of Clostridium Difficile Infection (CDI) in Hospitalized Patients Receiving Concomitant Antibiotics for the Treatment of Concurrent Systemic Infections Recruiting NCT02692651 Phase 4 Fidaxomicin;Vancomycin
15 Prospective, Interventional, Phase IV Study, Evaluating the Efficacy and Safety of Teicoplanin (100-200 mg, Administered Orally Twice a Day) in Patients With Clostridium Difficile Infection-associated Diarrhea and Colitis Recruiting NCT04003818 Phase 4 TEICOPLANIN
16 A Randomized, Double-Blinded Placebo Controlled Study To Determine the Effectiveness of Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) Recruiting NCT04000555 Phase 4 Oral Vancomycin
17 Screening to Prophylax Against Clostridium Difficile Infection Recruiting NCT02996487 Phase 4 Vancomycin
18 Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection Recruiting NCT04138706 Phase 4 Vancomycin;Placebos
19 Historically-controlled Clinical Trial of the Efficacy and Safety of Bezlotoxumab (BEZLO) in Addition to Standard of Care (SOC) Vancomycin for the Treatment of Multi-recurrent Clostridium Difficile Infection (CDI) Recruiting NCT03880539 Phase 4 bezlotoxumab;Vancomycin Oral
20 Efficacy of Prophylactic Oral Vancomycin in Preventing Recurrent Clostridium Difficile Infection in Hospitalized Patients Requiring Antibiotics Active, not recruiting NCT03466502 Phase 4 Oral Vancomycin
21 Oral Zinc Supplementation Improving Growth and Reducing Morbidity on Very Low Birth Weight Infant Not yet recruiting NCT04050488 Phase 4 Zinc Sulfate;Placebos
22 Is Bezlotoxumab Effective, Tolerable and Cost Saving in Preventing Recurrent Clostridium Difficile Infections in Patients With Malignancies? An Exploratory Study Not yet recruiting NCT04415918 Phase 4 Bezlotoxumab Injection
23 The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study Terminated NCT00164099 Phase 4 Synbiotic 2000
24 Protocol CHUM 2014-5056: A Randomized, Double Blinded Placebo Controlled Study to Evaluate the Efficacy of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea in Hospitalized Patients Terminated NCT01972932 Phase 4
25 Addition of a Probiotic (Lactobacillus GG) to Metronidazole for the Treatment of Clostridium Difficile Associated Disease Withdrawn NCT00304863 Phase 4 Lactobacillus GG
26 Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection Withdrawn NCT02464306 Phase 4 fidaxomicin
27 Role Of Saccharomyces Boulardii in Preventin Necrotizing Enterocolitis in Very Low Birth Weight Infants Unknown status NCT01315821 Phase 3 Saccharomyces boulardii;Placebo
28 Effect of Cysteine Supplementation on Glutathione Production in Critically Ill Neonates Unknown status NCT00254176 Phase 2, Phase 3
29 Transplantation of Fecal Microbiota for Clostridium Difficile Infection Unknown status NCT01958463 Phase 3
30 Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates Completed NCT00846963 Phase 2, Phase 3 Ursodiol;placebo
31 Effect of Vitamin A in the Treatment of Sepsis and Necrotizing Enterocolitis in Hospitalized Neonates Completed NCT00707785 Phase 3
32 Nosocomial Infections and Necrotizing Enterocolitis in Preterm Neonates Treated With Lactobacillus Acidophilus and Bifidobacterium Infantis in An Intensive Care Unit : A Randomized Controlled Study Completed NCT01340469 Phase 3
33 Role of Probiotics for Prevention of Necrotizing Enterocolitis in Preterm Very Low Birth Weight Infants: A Double Blind Randomized Controlled Trial Completed NCT02650869 Phase 3
34 Role Of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis in Very Low Birth Weight Infants Completed NCT01531179 Phase 3 Lactobacillus reuteri;Placebo
35 Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy Completed NCT00304356 Phase 3 Nitazoxanide
36 A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole, in Patients With C.Difficile - Associated Diarrhea Completed NCT00106509 Phase 3 tolevamer potassium-sodium (GT267-004)
37 The Efficacy of Symbiotic Preparation on Cytokines Which Act on Necrotising Enterocolitis Pathogenesis in Very Low Birth Weight Infants Completed NCT01899677 Phase 3 symbiotic
38 Prospective, Randomized Study of Oral Metronidazole vs. Oral Metronidazole and Rifampin for Treatment of Clostridium Difficile-associated Diarrhea (CDAD) Completed NCT00182429 Phase 3 Metronidazole and Rifampin
39 The Use of Probiotics in the Management of Necrotizing Enterocolitis in HIV-exposed Premature and Very-low Birth Weight Infants Completed NCT01868737 Phase 3
40 A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea Completed NCT00196794 Phase 3 Tolevamer potassium-sodium (GT267-004)
41 A Prospective, Multi-center, Randomized Trial of Fecal Microbiota Transplantation (FMT) Delivered by Capsule vs Colonoscopy in the Management of Recurrent Clostridium Difficile Infection (CDI) Completed NCT02254811 Phase 2, Phase 3
42 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY II) Completed NCT01513239 Phase 3 SOC
43 Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection Completed NCT02743234 Phase 3 Fidaxomicin;Vancomycin
44 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I) Completed NCT01241552 Phase 3 SOC
45 A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile Infection Completed NCT03244644 Phase 3 RBX2660;Placebo
46 Nordic Study on Human Milk Fortification in Extremely Preterm Infants: a Randomized Controlled Trial Recruiting NCT03797157 Phase 2, Phase 3
47 Can Bovine Lactoferrin Prevent Neonatal Infections in Low Birth Weight Babies in Karachi, Sindh, Pakistan. Recruiting NCT03431558 Phase 3 Glucon-D 99.4% (Placebo)
48 Evaluation of Bowel Perfusion With Contrast-Enhanced Ultrasound in Necrotizing Enterocolitis Recruiting NCT03549507 Phase 3 Sulfur hexafluoride lipid-type A microspheres
49 A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection Study Recruiting NCT03978000 Phase 3 IBP-9414;Placebo
50 COmparative Effectiveness of intestinaL microbiOta Versus vaNcomycin for Primary c. Difficile Infection - randomiZEd Trials Recruiting NCT03796650 Phase 3 Vancomycin

Search NIH Clinical Center for Enterocolitis

Sources

Genetic Tests for Enterocolitis

About this section

Genetic tests related to Enterocolitis:

# Genetic test Affiliating Genes
1 Enterocolitis 29
Sources

Anatomical Context for Enterocolitis

About this section

MalaCards organs/tissues related to Enterocolitis:

40
Breast, Heart, Lung, Liver, Colon, Kidney, Brain
Sources

Publications for Enterocolitis

About this section

Articles related to Enterocolitis:

(show top 50) (show all 12260)
# Title Authors PMID Year
1
Early lethal autosomal recessive enterocolitis: report of a second family. 61 57
17204052 2007
2
A lethal autosomal recessive entero-colitis of early infancy. 57
4426135 1974
3
[Gastrointestinal abnormalities in children with autism]. 61 54
19650428 2009
4
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. 54 61
16710025 2006
5
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. 54 61
16224277 2005
6
A human yeast artificial chromosome containing the multiple endocrine neoplasia type 2B Ret mutation does not induce medullary thyroid carcinoma but does support the growth of kidneys and partially rescues enteric nervous system development in Ret-deficient mice. 54 61
15632018 2005
7
Inflammatory changes secondary to postoperative complications of Hirschsprung's disease as a cause of histopathologic changes typical of intestinal neuronal dysplasia. 54 61
14966730 2004
8
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. 61 54
12826605 2003
9
Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra-abdominal infections. 54 61
7553416 1995
10
Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. 61 54
7532192 1995
11
Food protein-induced enterocolitis to casein hydrolysate formulas. 54 61
8258625 1993
12
Early total enteral feeding in stable preterm infants: a systematic review and meta-analysis. 61
31248308 2021
13
The relationship between histologic chorioamnionitis and decidual macrophage polarization and their influence on outcomes of neonates born before the 32nd gestational week. 61
31258026 2021
14
Reducing Underdiagnosis of Hirschsprung-Associated Enterocolitis: A Novel Scoring System. 61
33460971 2021
15
Impact of Botulinum Toxin on Hirschsprung-Associated Enterocolitis After Primary Pull-Through. 61
33422904 2021
16
ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab. 61
32691143 2021
17
TMEM16A deficiency: a potentially fatal neonatal disease resulting from impaired chloride currents. 61
32487539 2021
18
The Use of Fecal Calprotectin Testing in Paediatric Disorders: A Position Paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee. 61
33716293 2021
19
Chemotherapy-induced bowel ischemia: diagnostic imaging overview. 61
33811514 2021
20
Epidemiology of non-IgE-mediated food allergies: what can we learn from that? 61
33394702 2021
21
Gastrointestinal Zygomycosis in a Preterm Neonate Associated With Contaminated Probiotics. 61
33464011 2021
22
Transverse Colonic Perforation in Renal Transplant Recipients During the Early Postoperative Period: A Case Series. 61
33573821 2021
23
Short-chain fatty acid butyrate, a breast milk metabolite, enhances immature intestinal barrier function genes in response to inflammation in vitro and in vivo. 61
33085904 2021
24
Risk factors for re-hospitalization following neonatal discharge of extremely preterm infants in Canada. 61
33747317 2021
25
Cord blood eosinophilia precedes neonatal onset of food-protein-induced enterocolitis syndrome (FPIES). 61
33214086 2021
26
Food protein-induced enterocolitis syndrome triggered by egg yolk and egg white. 61
33176014 2021
27
Prophylactic efficacy of enteral antifungal administration of miconazole for intestinal perforation, especially for necrotizing enterocolitis: a historical cohort study at a single institution. 61
32886209 2021
28
Post-operative enterocolitis in Hirschsprung's disease: response to a Letter to the Editor. 61
33590304 2021
29
Poor prognosis of food protein-induced enterocolitis syndrome to fish. 61
33336438 2021
30
Dynamics of the preterm gut microbiome in health and disease. 61
33439103 2021
31
Untwisting the complexity of midgut malrotation and volvulus ultrasound. 61
33398405 2021
32
Inpatient management of Hirschsprung's associated enterocolitis treatment: the benefits of standardized care (Svetanoff WJ et al., Pediatr Surg Int (2020) 26:1413-1421). 61
33496824 2021
33
Epidemiology of coronavirus disease 2019 in pregnancy: risk factors and associations with adverse maternal and neonatal outcomes. 61
32986989 2021
34
False tolerant food challenges in children with food protein-induced enterocolitis syndrome. 61
33685614 2021
35
Neurodevelopmental and Growth Outcomes of Extremely Preterm Infants with Short Bowel Syndrome. 61
33246015 2021
36
High versus standard volume enteral feeds to promote growth in preterm or low birth weight infants. 61
33733486 2021
37
Safety and efficacy of human milk-based fortifier in enterally fed preterm and/or low birthweight infants: a systematic review and meta-analysis. 61
32943531 2021
38
The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study. 61
33803735 2021
39
Influence of Patient Characteristics on Antibiotic Use Rates Among Preterm Infants. 61
32170951 2021
40
Histopathology of non-IBD colitis practical recommendations from pathologists of IG-IBD Group. 61
33712395 2021
41
Evaluation of the Arabin cervical pessary for prevention of preterm birth in women with a twin pregnancy and short cervix (STOPPIT-2): An open-label randomised trial and updated meta-analysis. 61
33780463 2021
42
Extrauterine growth restriction in extremely preterm infants based on the Intergrowth-21st Project Preterm Postnatal Follow-up Study growth charts and the Fenton growth charts. 61
32909099 2021
43
Managing acute uncomplicated appendicitis in frail geriatric patients: A second hit may be too much. 61
33617197 2021
44
Galectin-4 as a Novel Biomarker of Neonatal Intestinal Injury. 61
33738671 2021
45
Neonatal surgical outcomes: a prospective observational study at a Tertiary Academic Hospital in Johannesburg, South Africa. 61
33740107 2021
46
Quantifying Medication Exposure in Very Low Birth Weight Neonates. 61
31683322 2021
47
Efficacy of Single-Strain Probiotics Versus Multi-Strain Mixtures: Systematic Review of Strain and Disease Specificity. 61
32274669 2021
48
A preoperative standardized feeding protocol improves human milk use in infants with complex congenital heart disease. 61
33547410 2021
49
Early infections after successful transcatheter aortic valve replacement are associated with increased short- and long-term mortality: A single-center study. 61
33785390 2021
50
Discovery of Novel Small-Molecule FAK Activators Promoting Mucosal Healing. 61
33738062 2021
Sources

Variations for Enterocolitis

About this section
Sources

Expression for Enterocolitis

About this section
Search GEO for disease gene expression data for Enterocolitis.
Sources

Pathways for Enterocolitis

About this section

Pathways related to Enterocolitis according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.84 TNF TLR4 NLRC4 IL6 IL10 CXCL8
2
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.13 TNF TLR4 IL6 IL10 CXCL8 CD14
3
Human cytomegalovirus infection 36
Show member pathways
 12.88 TNF TLR4 IL6 CXCL8 C3
4
Allograft rejection 36 1
Show member pathways
 12.81 TNF IL6 IL10 CXCL8 C3
5
Measles 36
Show member pathways
 12.78 TNF TLR4 IL6 CXCL8 CD46
6
Salmonella infection (KEGG) 36
Show member pathways
 12.68 TNF TLR4 NLRC4 IL6 CXCL8 CD14
7
T cell receptor signaling pathway 36
Show member pathways
 12.55 TNF TLR4 IL6 IL10
8
Th17 cell differentiation 36
Show member pathways
 12.54 TNF TLR4 IL6 IL10
9
Immune response IL-23 signaling pathway 23
Show member pathways
 12.53 TNF IL6 IL10 CD14
10
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.34 TNF TLR4 NLRC4 IL6 CXCL8 CD14
11
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.31 TNF IL6 IL10 CXCL8
12
Shigellosis 36
12.3 TNF TLR4 NLRC4 CXCL8 CD14 C3
13
Toll Comparative Pathway 63
Show member pathways
 12.28 TNF TLR4 IL6 CXCL8 CD14
14
Toxoplasmosis 36
Show member pathways
 12.24 TNF TLR4 IL10 C3
15
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.21 TNF IL6 IL10 CXCL8
16
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.21 TNF TLR4 IL6 CXCL8 CD14
17
NOD-like receptor signaling pathway 36
12.18 TNF TLR4 NLRC4 IL6 CXCL8
18
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.17 TNF IL6 IL10 CXCL8
19
Immune response Lectin induced complement pathway 23
Show member pathways
 12.16 CFH CFB CD46 C3
20
Tuberculosis 36
12.14 TNF TLR4 IL6 IL10 CD14 C3
21
Creation of C4 and C2 activators 65
Show member pathways
 12.11 CFH CFB CD46 C3
22
Complement and coagulation cascades 36 1
12.11 CFH CFB CD46 C3
23
Bacterial infections in CF airways 23
Show member pathways
 12.11 TNF TLR4 IL6 CXCL8 CD14
24
Phagosome 36
12.07 TLR4 CD14 C3
25
Spinal Cord Injury 1
12.02 TNF TLR4 IL6 CXCL8
26
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12 TNF IL6 IL10 CD14
27
Interleukin-4 and 13 signaling 65
11.99 TNF IL6 IL10 CXCL8
28
NF-kappa B signaling pathway 36
11.94 TNF TLR4 CXCL8 CD14
29
Yersinia infection 36
11.94 TNF TLR4 NLRC4 IL6 IL10 CXCL8
30
Staphylococcus aureus infection 36
11.9 IL10 CFH CFB C3
31
AGE-RAGE signaling pathway in diabetic complications 36
11.87 TNF IL6 CXCL8
32
Rheumatoid arthritis 36
11.87 TNF TLR4 IL6 CXCL8
33
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.87 TLR4 IL6 CXCL8 CD14
34
Hematopoietic cell lineage 36
11.86 TNF IL6 CD14
35
Th1 Differentiation Pathway 64
Show member pathways
 11.76 TNF TLR4 IL6 IL10
36
Dendritic Cells Developmental Lineage Pathway 64
11.74 TNF IL6 IL10 CD14
37
IgA-Producing B Cells in the Intestine 64
11.67 TNF TLR4 IL6 IL10
38
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.66 TNF IL6 CXCL8
39
Lung fibrosis 1
11.66 TNF IL6 CXCL8
40
Amoebiasis 36
11.64 TNF TLR4 IL6 IL10 CXCL8 CD14
41
Transcription_NF-kB signaling pathway 23
11.58 TNF TLR4 CD14
42
Interleukin-10 signaling 65
11.47 TNF IL6 IL10 CXCL8
43
Malaria 36
11.47 TNF TLR4 IL6 IL10 CXCL8
44
African trypanosomiasis 36
11.4 TNF IL6 IL10
45
Pertussis 36
11.38 TNF TLR4 IL6 IL10 CXCL8 CD14
46
Cytokines and Inflammatory Response 1
11.28 TNF IL6 IL10
47
IL-10 Pathway 63
11.2 TNF TLR4 IL6 IL10 CD14
48
Overview of nanoparticle effects 1
11.07 TNF IL6 CXCL8
49
Transcription factor regulation in adipogenesis 1
11.05 TNF IL6
50
Legionellosis 36
10.92 TNF TLR4 NLRC4 IL6 CXCL8 CD14
Sources

GO Terms for Enterocolitis

About this section

Cellular components related to Enterocolitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 TNF IL6 IL10 CXCL8 CFH CFB
2 cell surface GO:0009986 9.65 TNF TLR4 CD46 CD14 C3
3 blood microparticle GO:0072562 9.5 CFH CFB C3
4 extracellular space GO:0005615 9.23 TNF IL6 IL10 CXCL8 CFH CFB
5 lipopolysaccharide receptor complex GO:0046696 8.96 TLR4 CD14

Biological processes related to Enterocolitis according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 TNF TLR4 IL6 CXCL8 CD46
2 cytokine-mediated signaling pathway GO:0019221 9.95 TNF IL6 IL10 CXCL8
3 immune system process GO:0002376 9.95 TLR4 NLRC4 CFH CFB CD46 CD14
4 defense response to bacterium GO:0042742 9.92 TNF TLR4 NLRC4 IL10
5 immune response GO:0006955 9.91 TNF TLR4 IL6 IL10 CXCL8 C3
6 response to bacterium GO:0009617 9.86 TLR4 CD14 C3
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.86 TNF IL6 IL10
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 TNF TLR4 NLRC4 IL6
9 complement activation GO:0006956 9.85 CFH CFB C3
10 positive regulation of interleukin-6 production GO:0032755 9.84 TNF TLR4 IL6
11 positive regulation of tumor necrosis factor production GO:0032760 9.83 TLR4 IL6 CD14
12 negative regulation of interleukin-6 production GO:0032715 9.82 TNF TLR4 IL10
13 apoptotic signaling pathway GO:0097190 9.79 TNF TLR4 CD14
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.79 TNF TLR4 CD14
15 response to glucocorticoid GO:0051384 9.78 TNF IL6 IL10
16 regulation of complement activation GO:0030449 9.78 CFH CFB CD46 C3
17 positive regulation of interferon-gamma production GO:0032729 9.77 TNF TLR4 CD14
18 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.76 TNF TLR4 CD14
19 positive regulation of cytokine production GO:0001819 9.75 TNF IL10 CD14
20 positive regulation of chemokine production GO:0032722 9.72 TNF TLR4 IL6
21 necroptotic process GO:0070266 9.71 TLR4 CD14
22 positive regulation of macrophage activation GO:0043032 9.71 TLR4 IL10
23 positive regulation of interleukin-10 production GO:0032733 9.71 TLR4 IL6 CD46
24 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.7 TLR4 CD14
25 positive regulation of immunoglobulin production GO:0002639 9.7 IL6 IL10
26 toll-like receptor 4 signaling pathway GO:0034142 9.7 TLR4 CD14
27 positive regulation of glial cell proliferation GO:0060252 9.7 TNF IL6
28 positive regulation of JAK-STAT cascade GO:0046427 9.7 TNF IL6 IL10
29 innate immune response GO:0045087 9.7 TLR4 NLRC4 CFH CFB CD46 CD14
30 embryonic digestive tract development GO:0048566 9.69 TNF CXCL8
31 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 TNF IL10
32 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.69 TNF IL6
33 lipopolysaccharide-mediated signaling pathway GO:0031663 9.69 TNF TLR4 CD14
34 positive regulation of neuroinflammatory response GO:0150078 9.68 TNF IL6
35 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 TLR4 IL10
36 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.67 TNF TLR4
37 cellular response to lipoteichoic acid GO:0071223 9.67 TLR4 CD14
38 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.67 TNF TLR4 IL6
39 negative regulation of lipid storage GO:0010888 9.65 TNF IL6
40 endothelial cell apoptotic process GO:0072577 9.65 TNF IL10
41 regulation of complement-dependent cytotoxicity GO:1903659 9.64 IL10 CFH
42 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.63 TLR4 CD14
43 vascular endothelial growth factor production GO:0010573 9.63 TNF IL6
44 complement activation, alternative pathway GO:0006957 9.63 CFH CFB C3
45 positive regulation of interleukin-8 production GO:0032757 9.62 TNF TLR4 IL6 CD14
46 negative regulation of cytokine production involved in immune response GO:0002719 9.6 TNF IL10
47 positive regulation of interleukin-1 beta production GO:0032731 9.56 TNF TLR4 NLRC4 IL6
48 response to molecule of bacterial origin GO:0002237 9.54 IL10 CXCL8 CD14
49 inflammatory response GO:0006954 9.5 TNF TLR4 NLRC4 IL6 CXCL8 CD14
50 cellular response to lipopolysaccharide GO:0071222 9.1 TNF TLR4 IL6 IL10 CXCL8 CD14

Molecular functions related to Enterocolitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 TNF IL6 IL10 CXCL8
Sources

Sources for Enterocolitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....